CCL2 and neoplasm: In xenograft tumors derived from CCL2‐secreting 786‐O cells, CCL2NA treatment suppressed tumor growth accompanied with a decreased MVD (Fig. S5A, C, and D), and these effects were comparable to those with bevacizumab treatment (Fig. S5B, C, and D).